Colobreathe colistimethate sodium regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Colobreathe colistimethate sodium from Forest Labs to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis (CF) patients - its approved indication. Comments are due Nov. 13, with a second appraisal committee meeting scheduled for Nov. 27. Final guidance is expected in March 2013. ...